U.S. markets close in 2 hours 47 minutes
  • S&P 500

    4,439.40
    -34.35 (-0.77%)
     
  • Dow 30

    34,588.54
    -162.78 (-0.47%)
     
  • Nasdaq

    15,054.54
    -127.38 (-0.84%)
     
  • Russell 2000

    2,235.49
    +2.58 (+0.12%)
     
  • Crude Oil

    71.82
    -0.79 (-1.09%)
     
  • Gold

    1,752.90
    -3.80 (-0.22%)
     
  • Silver

    22.42
    -0.38 (-1.66%)
     
  • EUR/USD

    1.1730
    -0.0041 (-0.35%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3744
    -0.0053 (-0.38%)
     
  • USD/JPY

    109.9700
    +0.2520 (+0.23%)
     
  • BTC-USD

    47,610.81
    -406.29 (-0.85%)
     
  • CMC Crypto 200

    1,208.61
    -16.92 (-1.38%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., July 29, 2021--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update.

To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 4156527. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005069/en/

Contacts

Media Contact:
Naomi Aoki
Syros Pharmaceuticals
617-283-4298
naoki@syros.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com